Detailed information for compound 212554

Basic information

Technical information
  • Name: Unnamed compound
  • MW: 337.372 | Formula: C19H19N3O3
  • H donors: 3 H acceptors: 3 LogP: 3.27 Rotable bonds: 6
    Rule of 5 violations (Lipinski): 1
  • SMILES: OC(=O)CNc1cccn2c1c(C(=O)N)c(c2Cc1ccccc1)C
  • InChi: 1S/C19H19N3O3/c1-12-15(10-13-6-3-2-4-7-13)22-9-5-8-14(21-11-16(23)24)18(22)17(12)19(20)25/h2-9,21H,10-11H2,1H3,(H2,20,25)(H,23,24)
  • InChiKey: SGEIYUDGOUMHKL-UHFFFAOYSA-N  

Network

Hover on a compound node to display the structore

Synonyms

No synonyms found for this compound

Targets

Known targets for this compound

No curated genes were found associated with this compound

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity

Obtained from network model

Ranking Plot


Putative Targets List


Species Potential target Raw Global Species
Trichomonas vaginalis Clan AA, family A1, cathepsin D-like aspartic peptidase 0.0048 0.221 1
Wolbachia endosymbiont of Brugia malayi dihydrolipoamide dehydrogenase E3 component 0.0021 0 0.5
Loa Loa (eye worm) glutathione reductase 0.0061 0.3372 1
Mycobacterium ulcerans dihydrolipoamide dehydrogenase, LpdB 0.0021 0 0.5
Mycobacterium tuberculosis NADPH-dependent mycothiol reductase Mtr 0.0061 0.3372 1
Plasmodium falciparum thioredoxin reductase 0.0061 0.3372 1
Plasmodium vivax thioredoxin reductase, putative 0.0061 0.3372 1
Brugia malayi Thioredoxin reductase 0.0061 0.3372 1
Leishmania major trypanothione reductase 0.0061 0.3372 1
Echinococcus granulosus thioredoxin glutathione reductase 0.0061 0.3372 1
Wolbachia endosymbiont of Brugia malayi dihydrolipoamide dehydrogenase E3 component 0.0021 0 0.5
Plasmodium falciparum plasmepsin II 0.0048 0.221 0.6554
Toxoplasma gondii aspartyl proteinase (eimepsin), putative 0.0048 0.221 0.6554
Plasmodium falciparum plasmepsin IV 0.0048 0.221 0.6554
Brugia malayi glutathione reductase 0.0061 0.3372 1
Plasmodium falciparum plasmepsin VI 0.0048 0.221 0.6554
Plasmodium vivax aspartyl proteinase, putative 0.0048 0.221 0.6554
Echinococcus multilocularis thioredoxin glutathione reductase 0.0061 0.3372 1
Schistosoma mansoni cathepsin D (A01 family) 0.014 1 1
Schistosoma mansoni subfamily A1A unassigned peptidase (A01 family) 0.0048 0.221 0.221
Mycobacterium leprae DIHYDROLIPOAMIDE DEHYDROGENASE LPD (LIPOAMIDE REDUCTASE (NADH)) (LIPOYL DEHYDROGENASE) (DIHYDROLIPOYL DEHYDROGENASE) (DIAPHORASE 0.0021 0 0.5
Trypanosoma cruzi trypanothione reductase, putative 0.0061 0.3372 1
Plasmodium vivax glutathione reductase, putative 0.0061 0.3372 1
Plasmodium vivax plasmepsin IV, putative 0.0048 0.221 0.6554
Loa Loa (eye worm) thioredoxin reductase 0.0061 0.3372 1
Giardia lamblia NADH oxidase lateral transfer candidate 0.0021 0 0.5
Trypanosoma brucei trypanothione reductase 0.0061 0.3372 1
Mycobacterium ulcerans flavoprotein disulfide reductase 0.0021 0 0.5
Toxoplasma gondii thioredoxin reductase 0.0061 0.3372 1
Treponema pallidum NADH oxidase 0.0021 0 0.5
Echinococcus granulosus cathepsin d lysosomal aspartyl protease 0.0048 0.221 0.6554
Plasmodium falciparum glutathione reductase 0.0061 0.3372 1
Chlamydia trachomatis dihydrolipoyl dehydrogenase 0.0021 0 0.5
Mycobacterium ulcerans dihydrolipoamide dehydrogenase 0.0021 0 0.5
Toxoplasma gondii aspartyl protease ASP1 0.0048 0.221 0.6554
Plasmodium falciparum plasmepsin I 0.0048 0.221 0.6554
Echinococcus multilocularis cathepsin d (lysosomal aspartyl protease) 0.0048 0.221 0.6554

Activities

Activity type Activity value Assay description Source Reference
IC50 (binding) = 22 uM Inhibition of recombinant human secretory phospholipase A2 (sPLA2), chromogenic screening assay. ChEMBL. 8809154
IC50 (binding) = 22 uM Inhibition of recombinant human secretory phospholipase A2 (sPLA2), chromogenic screening assay. ChEMBL. 8809154

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

No external resources registered for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.